Literature DB >> 19602603

Amino Acid-based peritoneal dialysis solutions for malnutrition: new perspectives.

Hoey Lan Tjiong1, Roel Swart, Jacobus W van den Berg, Marien W Fieren.   

Abstract

Protein and energy malnutrition is frequently found in patients on maintenance dialysis and is associated with an increased risk of death. Among a variety of factors involved in the development of protein and energy malnutrition, such as acidosis, insulin resistance, inflammation, and dialysate protein losses, insufficient intake of proteins and energy as a result of anorexia plays a prominent role. Amino acid (AA)-based peritoneal dialysis (PD) solutions can induce an anabolic response in malnourished patients on continuous ambulatory PD if enough calories are ingested simultaneously. Poor appetite, however, may impede the intake of sufficient calories. Peritoneal dialysis solutions containing a mixture of AAs and glucose in a proper ratio can serve as a source of proteins and calories. Such a dialysis solution can be used in fasting patients on nocturnal automated PD as part of a regular dialysis schedule. Using a sophisticated technique involving stable isotopes, this dialysis mixture has been found to induce acute anabolic changes in whole body protein metabolism. Such a metabolic response is similar to that induced by food. Intraperitoneal AAs, in common with ingested proteins, can induce generation of hydrogen ions and urea through oxidation of specific AAs. Supplying AAs together with calories could bring about utilization of AAs for the synthesis of proteins rather than the oxidation of AAs, thereby limiting production of acid and urea. Using dialysis solutions with a buffer concentration of 40 mmol/L further contributes to maintaining acid-base homeostasis. We advocate consideration of usage of AA/glucose dialysate when PD patients cannot comply with dietary requirements. To evaluate the long-term effects of this approach on morbidity and mortality, clinical trials with large groups of patients are needed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19602603

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  6 in total

1.  Tolvaptan increases urine and ultrafiltration volume for patients with oliguria undergoing peritoneal dialysis.

Authors:  Tohru Iwahori; Masatoshi Esaki; Hayao Hinoue; Shinga Esaki; Yukumi Esaki
Journal:  Clin Exp Nephrol       Date:  2013-10-11       Impact factor: 2.801

2.  Diagnosis and management of chronic kidney disease in the elderly: a field of ongoing debate.

Authors:  Periklis Dousdampanis; Konstantina Trigka; Costas Fourtounas
Journal:  Aging Dis       Date:  2012-08-06       Impact factor: 6.745

3.  Peritoneal dialysis in diabetics: there is room for more.

Authors:  P Cotovio; A Rocha; A Rodrigues
Journal:  Int J Nephrol       Date:  2011-10-16

4.  Ontogeny-driven rDNA rearrangement, methylation, and transcription, and paternal influence.

Authors:  Yih-Horng Shiao; Robert M Leighty; Cuiju Wang; Xin Ge; Erik B Crawford; Joshua M Spurrier; Sean D McCann; Janet R Fields; Laura Fornwald; Lisa Riffle; Craig Driver; Octavio A Quiñones; Ralph E Wilson; Kazimierz S Kasprzak; Gregory S Travlos; W Gregory Alvord; Lucy M Anderson
Journal:  PLoS One       Date:  2011-07-12       Impact factor: 3.240

Review 5.  Nutritional Status in Peritoneal Dialysis: Nutritional Guidelines, Adequacy and the Management of Malnutrition.

Authors:  Thomas Kiebalo; Jacqueline Holotka; Ireneusz Habura; Krzysztof Pawlaczyk
Journal:  Nutrients       Date:  2020-06-08       Impact factor: 5.717

6.  Education and Protein Supplementation Improve Nutritional Biomarkers among Hypoalbuminemic Peritoneal Dialysis Patients: A Quasi-Experimental Design.

Authors:  Tuyen Van Duong; Chang-An Tsao; Evelyn Yang; Ching-Hsiu Peng; Yi-Cheng Hou; Yan-Chen Su; Jui-Ting Chang; Shwu-Huey Yang
Journal:  Healthcare (Basel)       Date:  2019-11-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.